Achieve Life Sciences (ACHV) Convertible Debt (2021 - 2026)

Achieve Life Sciences' Convertible Debt history runs 6 years deep, the most recent figure standing at $9.3 million for Q1 2026.

• Quarterly Convertible Debt rose 7.68% year-over-year to $9.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.3 million (up 7.68% YoY) and the FY2025 annual result came in at $11.2 million, up 13.7% from the prior year.
• Convertible Debt was $9.3 million for Q1 2026 at Achieve Life Sciences, down from $11.2 million in the prior quarter.
• Across five years, Convertible Debt topped out at $16.2 million in Q3 2023 and bottomed at $8.7 million in Q1 2025.
• A 5-year average of $11.8 million and a median of $9.8 million in 2024 frame the typical range for Convertible Debt.
• Annual changes were most pronounced in 2024 — Convertible Debt slumped 44.03% — and 2025, when it grew 13.7%.
• Achieve Life Sciences' Convertible Debt stood at $15.8 million in 2022, then grew by 2.74% to $16.2 million in 2023, then slumped by 39.26% to $9.8 million in 2024, then rose by 13.7% to $11.2 million in 2025, then declined by 16.66% to $9.3 million in 2026.
• Business Quant data shows ACHV's Convertible Debt at $9.3 million in Q1 2026, $11.2 million in Q4 2025, and $8.7 million in Q3 2025.